About: Antiviral Activity of Glycyrrhizin against Hepatitis C Virus In Vitro

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral Activity of Glycyrrhizin against Hepatitis C Virus In Vitro Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antiviral Activity of Glycyrrhizin against Hepatitis C Virus In Vitro
Creator	Wakita, Takaji Watashi, Koichi Miyamura, Tatsuo Suzuki, Tetsuro Aizaki, Hideki Aoyagi, Haruyo Date, Tomoko Ichinose, Shizuko Matsuda, Mami Matsumoto, Yoshihiro Matsuura, Tomokazu Suzuki, Ryosuke Wake, Kenjiro Watanabe, Noriyuki Polyak, Stephen Hmwe, Su
Source	Medline; PMC
abstract	Glycyrrhizin (GL) has been used in Japan to treat patients with chronic viral hepatitis, as an anti-inflammatory drug to reduce serum alanine aminotransferase levels. GL is also known to exhibit various biological activities, including anti-viral effects, but the anti-hepatitis C virus (HCV) effect of GL remains to be clarified. In this study, we demonstrated that GL treatment of HCV-infected Huh7 cells caused a reduction of infectious HCV production using cell culture-produced HCV (HCVcc). To determine the target step in the HCV lifecycle of GL, we used HCV pseudoparticles (HCVpp), replicon, and HCVcc systems. Significant suppressions of viral entry and replication steps were not observed. Interestingly, extracellular infectivity was decreased, and intracellular infectivity was increased. By immunofluorescence and electron microscopic analysis of GL treated cells, HCV core antigens and electron-dense particles had accumulated on endoplasmic reticulum attached to lipid droplet (LD), respectively, which is thought to act as platforms for HCV assembly. Furthermore, the amount of HCV core antigen in LD fraction increased. Taken together, these results suggest that GL inhibits release of infectious HCV particles. GL is known to have an inhibitory effect on phospholipase A2 (PLA2). We found that group 1B PLA2 (PLA2G1B) inhibitor also decreased HCV release, suggesting that suppression of virus release by GL treatment may be due to its inhibitory effect on PLA2G1B. Finally, we demonstrated that combination treatment with GL augmented IFN-induced reduction of virus in the HCVcc system. GL is identified as a novel anti-HCV agent that targets infectious virus particle release.
has issue date	2013-07-18(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0068992
bibo:pmid	23874843
has license	cc-by
sha1sum (hex)	a2e8d9291e399c6d8adc6d39318de197e86b3f4e
schema:url	https://doi.org/10.1371/journal.pone.0068992
resource representing a document's title	Antiviral Activity of Glycyrrhizin against Hepatitis C Virus In Vitro
has PubMed Central identifier	PMC3715454
has PubMed identifier	23874843
schema:publication	PLoS One
resource representing a document's body	covid:a2e8d9291e399c6d8adc6d39318de197e86b3f4e#body_text
is schema:about of	named entity 'determine' named entity 'platforms' named entity 'release' named entity 'HCV' named entity 'demonstrated' named entity 'target' named entity 'inhibitor' named entity 'inhibitory' named entity 'HCV' named entity 'GLYCYRRHIZIN' named entity 'IMMUNOFLUORESCENCE' named entity 'SYSTEMS' named entity 'MICROSCOPIC' named entity 'MAY BE' named entity 'AGENT' named entity 'USING' named entity 'INHIBITOR' named entity 'TREATED' named entity 'ENDOPLASMIC RETICULUM' named entity 'KNOWN' named entity 'EXTRACELLULAR' named entity 'COMBINATION' named entity 'ALANINE AMINOTRANSFERASE' named entity 'VIRUS' named entity 'STEP' named entity 'CHRONIC VIRAL HEPATITIS' named entity 'STEPS' named entity 'INFECTIVITY' named entity 'ACT' named entity 'NOT OBSERVED' named entity 'CELL' named entity 'HEPATITIS C VIRUS' named entity 'TARGET' named entity 'CELLS' named entity 'LEVELS' named entity 'TREAT' named entity 'VIRAL ENTRY' named entity 'ACTIVITIES' named entity 'FOUND' named entity 'ELECTRON' named entity 'INTRACELLULAR' named entity 'EXHIBIT' named entity 'VIRUS RELEASE' named entity 'BIOLOGICAL' named entity 'TREATMENT' named entity 'JAPAN' named entity 'SIGNIFICANT' named entity 'RELEASE' named entity 'VARIOUS' named entity 'INFECTIOUS' named entity 'SYSTEM' named entity 'ASSEMBLY' named entity 'ANTIVIRAL' named entity 'REPLICON' named entity 'ACCUMULATED' named entity 'ATTACHED TO' named entity 'DEMONSTRATED' named entity 'TAKEN' named entity 'REDUCTION' named entity 'ITS' named entity 'TARGETS' named entity 'EFFECTS' named entity 'VIRUS PARTICLE' named entity 'DECREASED' named entity 'EFFECT' named entity 'ANTIGENS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software